Intervju med Dr James Garner, VD Kazia Therapeutics
-
Regulatoriska pressmedddelanden 25 maj, 2022Kommuniké från årsstämma i Vivesto AB
-
Regulatoriska pressmedddelanden 25 maj, 2022Delårsrapport för perioden 1 januari – 31 mars 2022
-
Pressmeddelanden 18 maj, 2022Inbjudan till presentation av Vivestos Q1-rapport den 25 maj
Vivesto publicerade sin Q1 2022-rapport den 25 maj 2022, klockan 08.00 CET.
Oasmia förvärvar globala rättigheter för utveckling och kommersialisering av Cantrixil – ett kliniskt program inom äggstockscancer
Today we published our Q1 #Financial #Results.
In a challenging financial climate, we were pleased to successfully raise SEK 151m during the quarter and report operational progress on several fronts.
#oncology #biotech
Interim report for the period January 1, 2022 – March 31, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
bit.ly
Did you know that #WorldOvarianCancerDay is on May 8? We are proud to be developing new treatments that we hope may make a difference to patients. Learn more about ovarian cancer and check out its symptoms here:
#WOCD2022 #NoWomanLeftBehind
Home
The World Ovarian Cancer Coalition
worldovariancancercoalition.org
